Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review.

Yolcar Chamorro; Ana Sandoval Leon; Manmeet Ahluwalia; Reshma Mahtani; Naomi Dempsey

Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review.

Yolcar Chamorro
, Ana Sandoval Leon
, Manmeet Ahluwalia
, Reshma Mahtani
, Naomi Dempsey

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Jun 2 2023

Cite this

@conference{8aa2e0cd49f94cc8bd3a18748feb96a9,

title = "Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review.",

author = "Yolcar Chamorro and \{Sandoval Leon\}, Ana and Manmeet Ahluwalia and Reshma Mahtani and Naomi Dempsey",

year = "2023",

month = jun,

day = "2",

language = "American English",

}

TY - CONF

T1 - Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review.

AU - Chamorro, Yolcar

AU - Sandoval Leon, Ana

AU - Ahluwalia, Manmeet

AU - Mahtani, Reshma

AU - Dempsey, Naomi

PY - 2023/6/2

Y1 - 2023/6/2

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/4970

M3 - Presentation

ER -

Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review.

Other files and links

Cite this